What's Happening?
PepGen Inc. has announced favorable results from the lowest dose cohort of its Phase 2 FREEDOM2 study, evaluating PGN-EDODM1 for the treatment of myotonic dystrophy type 1 (DM1). The study showed that PGN-EDODM1 was well-tolerated, with all adverse events
being mild or moderate. The treatment demonstrated a mean splicing correction of 7.3%, with promising trends in muscle function improvement. The company is on track to report data from a higher dose cohort later in 2026, with sufficient funding to continue operations into 2027.
Why It's Important?
The development of PGN-EDODM1 is significant as it targets the root cause of DM1, a severe neuromuscular disease with limited treatment options. The positive safety and efficacy results from the FREEDOM2 study suggest that PGN-EDODM1 could become a viable therapeutic option for DM1 patients. The U.S. Food and Drug Administration has granted the drug both Orphan Drug and Fast Track Designations, highlighting its potential to address an unmet medical need.
What's Next?
PepGen plans to continue the FREEDOM2 study with a higher dose cohort, with results expected in the second half of 2026. The company is also enrolling patients in an open-label extension study to further evaluate the long-term safety and efficacy of PGN-EDODM1. These efforts are part of PepGen's broader strategy to develop next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases.
